Novartis | NVS - Zahlungsmittel Und Äquivalente

Aktienkurs
144.86
Täglich Wechseln
-2.67 -1.81%
Monatlich
-3.87%
Jährlich
29.08%
Q2 Prognose
142.62




Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 5.23B 400M 2025-12
Amgen USD 9.13B 316M 2025-12
AstraZeneca USD 8.14B 1.08B 2025-09
Bausch Health Companies USD 1.31B 419M 2025-09
Biogen USD 3.01B 854.3M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Canopy Growth CAD 371.32M 73.26M 2025-12
Corcept Therapeutics USD 120.49M 4.64M 2025-12
Drreddys Laboratories INR 18.66B 9.65B 2025-12
Eli Lilly USD 7.27B 2.52B 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
GlaxoSmithKline GBP 3.3B 303M 2025-09
Glaxosmithkline GBP 3.3B 303M 2025-09
J&J USD 21.69B 1.98B 2026-03
Merck USD 18.17B 10.16B 2025-09
Novartis USD 9.56B 2.9B 2025-09
Novartis USD 9.56B 2.9B 2025-09
Pacira USD 158.54M 10.96M 2025-12
Perrigo USD 432.1M 22.1M 2025-09
Pfizer USD 1.34B 295M 2025-09
Phibro Animal Health USD 55.49M 17.28M 2025-12
Prestige Brands USD 62.37M 56.73M 2025-12
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Sanofi EUR 7.66B 1.25B 2025-12
Supernus Pharmaceuticals USD 151.37M 6.66M 2025-09
Zoetis USD 2.08B 649M 2025-09